PF-Atlas › Treatments › uPAR-CAR-T Senolytic Immunotherapy
uPAR-CAR-T Senolytic Immunotherapy
CAR-T cells targeting uPAR (urokinase plasminogen activator receptor) on senescent cells — living drug senolytic
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Preclinical (MSK)
Evidence level
Level 2 (Preclinical→Phase I)
Mechanism class
CAR-T cells targeting uPAR (urokinase plasminogen activator receptor) on senescent cells — living drug senolytic
Timeline
3-5 years
Risk profile
Medium
Developer
Memorial Sloan Kettering
Key researchers
M. Amor / S. Lowe
Overview
Nature Aging 2023: single low-dose uPAR-CAR-T reversed liver fibrosis, improved exercise capacity in aged mice. Long-lasting prophylactic effect — a one-time living senolytic. Cell 2026: uPAR ecosystem approach overcomes antigen heterogeneity. LNP-delivered in-vivo CAR approach eliminates manufacturing bottleneck.
How uPAR-CAR-T Senolytic Immunotherapy fits into IPF treatment
uPAR-CAR-T Senolytic Immunotherapy is classified as Level 2 (Preclinical→Phase I) at the Preclinical (MSK) stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about uPAR-CAR-T Senolytic Immunotherapy for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.